Optimizing the Biocompatibility of PLLA Stent Materials: Strategy with Biomimetic Coating
DOI: https://doi.org/10.2147/ijn.s462691
IF: 7.033
2024-06-04
International Journal of Nanomedicine
Abstract:Hao Du, 1 Wentao Li, 1 Xueyi Li, 2 Zhiyuan Qiu, 1 Jie Ding, 2 Yi Zhang 1 1 Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Cultivation and Construction Site of the State Key Laboratory of Intelligent Imaging and Interventional Medicine, Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People's Republic of China; 2 Department of Biochemistry and Molecular Biology, Medical School, Southeast University, Nanjing, Jiangsu Province, People's Republic of China Correspondence: Jie Ding; Yi Zhang, Email ; Background: Poly-L-lactic acid (PLLA) stents have broad application prospects in the treatment of cardiovascular diseases due to their excellent mechanical properties and biodegradability. However, foreign body reactions caused by stent implantation remain a bottleneck that limits the clinical application of PLLA stents. To solve this problem, the biocompatibility of PLLA stents must be urgently improved. Albumin, the most abundant inert protein in the blood, possesses the ability to modify the surface of biomaterials, mitigating foreign body reactions—a phenomenon described as the "stealth effect". In recent years, a strategy based on albumin camouflage has become a focal point in nanomedicine delivery and tissue engineering research. Therefore, albumin surface modification is anticipated to enhance the surface biological characteristics required for vascular stents. However, the therapeutic applicability of this modification has not been fully explored. Methods: Herein, a bionic albumin (PDA-BSA) coating was constructed on the surface of PLLA by a mussel-inspired surface modification technique using polydopamine (PDA) to enhance the immobilization of bovine serum albumin (BSA). Results: Surface characterization revealed that the PDA-BSA coating was successfully constructed on the surface of PLLA materials, significantly improving their hydrophilicity. Furthermore, in vivo and in vitro studies demonstrated that this PDA-BSA coating enhanced the anticoagulant properties and pro-endothelialization effects of the PLLA material surface while inhibiting the inflammatory response and neointimal hyperplasia at the implantation site. Conclusion: These findings suggest that the PDA-BSA coating provides a multifunctional biointerface for PLLA stent materials, markedly improving their biocompatibility. Further research into the diverse applications of this coating in vascular implants is warranted. Keywords: vascular stent, Poly-L-lactic acid, albumin, biomimetic coating, stealth effect Graphical Cardiovascular diseases (CVDs) are increasingly becoming the leading cause of death worldwide, resulting in a serious public health burden. 1 Interventional therapy, which involves endovascular stenting (ES), is the most widespread and effective method for treating CVDs. 2,3 Currently, commonly used bare metal stents (BMSs) and drug-eluting stents (DESs) are made with nonbiodegradable metal materials and can support the initial stage of implantation to maintain vascular patency. 4,5 However, the risk of thrombosis and restenosis are often increased by permanent stent retention, which also hinders imaging evaluations and further clinical intervention. 6,7 Bioabsorbable vascular stents (BVSs) are becoming a new strategy to improve the long-term outcome of ES as BVSs degrade over time after they perform their supportive role, which facilitates revascularization and functional recovery. 8 Poly-L-lactic Acid (PLLA) is an ideal material for BVS due to its excellent biodegradability and mechanical properties; 9 in addition, PLLA has shown good degradation behavior and biosafety in clinical trials, with additional clinical evidence supporting its application. 10,11 Nevertheless, PLLA stents inevitably cause a foreign body reaction in host tissues, affecting the therapeutic efficacy of ES. 10,12 This reaction is attributed to platelet adhesion and immune cell activation, which occurs when the stent is sensed as an intravascular; 13,14 as a result, in-stent thrombosis and intimal hyperplasia ultimately occur. For these reasons, the interface between the PLLA stent and host tissue must be improved to mitigate foreign body reactions and achieve long-term patency and definitive efficacy of ES. In this context, a simple and effective camouflage strategy that involves "stealth" modifications of vascular implanted foreign bodies (eg, coating with natural biomaterials) deserves further investigation. Albumin is the most abundant plasma prot -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology